Pacific Biosciences upgraded to Neutral from Underweight at Piper Jaffray

theflyonthewall.com

Piper Jaffray upgraded Pacific Biosciences to Neutral citing increased stability following the company's Q2 results. The firm raised its price target for shares to $3.10 from $2.

View Comments (0)